Straits Times Index
3,348.87 +12.28 (+0.37%) S&P 500
5,283.40 +5.89 (+0.11%) Dow
38,571.03 -115.29 (-0.30%) Nasdaq
16,828.67 +93.65 (+0.56%) Bitcoin USD
68,934.78 +1,093.37 (+1.61%) CMC Crypto 200
1,446.92 -21.01 (-1.43%)
Valneva SE (INRLF)
| Previous close | 4.2546 |
| Open | 4.6200 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 4.5500 - 4.6200 |
| 52-week range | 3.3500 - 8.5500 |
| Volume | |
| Avg. volume | 1,190 |
| Market cap | 649.198M |
| Beta (5Y monthly) | 0.84 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2100 |
| Earnings date | 13 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireValneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases
Saint-Herblain (France), June 3, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the results of two Phase 2 clinical trials of Lyme disease vaccine candidate, VLA15, were published in the peer-reviewed medical journal, The Lancet Infectious Diseases. These trials, as well as a third Phase 2 trial in pediatric participants, supported the design of the current pivotal Phase 3 trial, ‘Vaccine Against Lyme for Outdoor Recreationists’ (VALOR).
- GlobeNewswire
Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine
If approved, IXCHIQ® will become the first vaccine available in the EU against the chikungunya virus (CHIKV)Decision on EU marketing authorization expected in the third quarter of 2024 Saint Herblain (France), May 31, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending authorization of Valneva’s single-do
- GlobeNewswire
Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer
Saint-Herblain (France), May 21, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the appointment of Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer (CSO) and Executive Committee member, effective June 3, 2024. Valneva decided to complement its Executive Team with an accomplished R&D leader to oversee the further evolution of the Company´s R&D portfolio. Specifically, Dr. Schuitemaker will focus on accelerating Valneva’s pre-clinical
